Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-04-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第一季度报告" which translates to "2025 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2025. The document includes comprehensive financial figures, analysis of changes in financial indicators, shareholder information, and other important matters relevant to the quarter. It is not a brief announcement or a certification but a full quarterly financial report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-25 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (Special Audit Report) concerning the 2024 non-operating fund occupation and other related party fund transactions of Harbin Yuheng Pharmaceutical Co., Ltd. It is issued by a certified public accounting firm and references the 2024 audited financial statements. The document includes detailed tables summarizing related party fund usage and transactions, and it explicitly states it is a special audit report prepared under Chinese CPA standards. It is not a full annual report but a standalone audit report focusing on a specific aspect of the company's financials (non-operating fund occupation and related party transactions). The document length is over 6000 characters and contains substantive financial data and audit opinion. Therefore, it fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a Regulatory Filing (RNS). FY 2024
2025-04-25 Chinese
关于2024年限制性股票激励计划首次授予部分第一个限售期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the achievement of the first unlocking condition of the first restricted stock incentive plan granted in 2024. It includes extensive information about the stock incentive plan, approval procedures, performance conditions, and legal opinions. The content focuses on the status and conditions of restricted stock awards and their unlocking, which is related to equity incentive plans and share-based compensation. It is not a financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement about the unlocking of restricted stock under an incentive plan, which fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and equity incentives. The document length (7540 characters) and detailed content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2025-04-25 Chinese
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2024 年度财务决算报告' which translates to '2024 Annual Financial Settlement Report'. It contains detailed financial statements including balance sheets, profit and loss statements, cash flow statements, and notes for the fiscal year ending December 31, 2024. The document includes audited financial data with a standard unqualified audit opinion. It covers comprehensive financial performance, business analysis, cash flow, and asset composition for the full fiscal year 2024. The length of the document (7605 characters) and the detailed financial data confirm it is a full annual report rather than a brief announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2024
2025-04-25 Chinese
内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of the company's internal control over financial reporting as of December 31, 2024. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document length is 1154 characters, indicating it is a standalone audit report rather than a full annual report or other type. There is no indication that this is an announcement or a certification letter only. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
董事会审计委员会对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the external audit firm for the fiscal year 2024. It discusses the audit firm's qualifications, audit procedures, communication with the audit firm, and overall assessment of the audit work related to the company's 2024 annual financial statements and internal control audit. The document does not contain the actual audited financial statements or detailed financial data but rather focuses on the audit firm's performance and the committee's oversight role. This type of document fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports. The document length is 2441 characters, which is sufficient for a detailed report but not a full annual report. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.